Harnessing Avidity-Based Binding Logic to Improve T-cell Engager Selectivity for Solid Tumors
- Integrating high-throughput functional cell-based assays with machine learning to enable rapid optimization of preclinical candidates
- Solving on-target/off-tumor toxicities through avidity-driven tumor selectivity
- Progressing our lead asset LGTX-101 (Nectin-4 x CD3 T-cell engager) through IND enabling studies demonstrating robust in vitro, in vivo and biophysical characteristics